Skip to main content
SpringerLink
Log in

Hohes Alter, Niereninsuffizienz und andere Komorbiditäten

Antikoagulation unter erschwerten Bedingungen

Anticoagulation and comorbidities

  • FORTBILDUNG . SCHWERPUNKT
  • Published:
MMW - Fortschritte der Medizin Aims and scope

Die orale Antikoagulation ist bei Begleiterkrankungen oft mit einem hohen Blutungsrisiko assoziiert. Der Artikel beleuchtet Komorbiditäten und ihren Einfluss auf die Antikoagulationsstrategie. Darüber hinaus zeigt er Unterschiede zwischen Vitamin-K-Antagonisten und Nicht-Vitamin-K-Antagonisten (NOAK) sowie innerhalb der NOAK-Substanzklasse auf.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Björck S, Palaszewski B, Friberg L, Bergfeldt L. Atrial fibrillation, stroke risk, and warfarin therapy revisited: a population-based study. Stroke. 2013 Nov;44(11):3103–8. doi: https://doi.org/10.1161/STROKEAHA.113.002329. Epub 2013 Aug 27.

    Article  CAS  PubMed  Google Scholar 

  2. Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998;98:946–952.

    Article  CAS  PubMed  Google Scholar 

  3. Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the longterm risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 2002;113:359–364.

    Article  PubMed  Google Scholar 

  4. Andersson T, Magnuson A, Bryngelsson IL, Frobert O, Henriksson KM, Edvardsson N, Poci D. All-cause mortality in 272,186 patients hospitalized with incident atrial fibrillation 1995-2008: a Swedish nationwide long-term casecontrol study. Eur Heart J 2013;34:1061–1067.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P, Agewall S, Camm J, Baron Esquivias G, Budts W, Carerj S, Casselman F, Coca A, De Caterina R, Deftereos S, Dobrev D, Ferro JM, Filippatos G, Fitzsimons D, Gorenek B, Guenoun M, Hohnloser SH, Kolh P, Lip GY, Manolis A, McMurray J, Ponikowski P, Rosenhek R, Ruschitzka F, Savelieva I, Sharma S, Suwalski P, Tamargo JL, Taylor CJ, Van Gelder IC, Voors AA, Windecker S, Zamorano JL, Zeppenfeld K. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardiothorac Surg. 2016 Nov;50(5):e1–e88. Epub 2016 Sep 23.

    Article  PubMed  Google Scholar 

  6. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010 Feb;137(2):263–72. doi: https://doi.org/10.1378/chest.09-1584. Epub 2009 Sep 17.

    Article  PubMed  Google Scholar 

  7. Jani BD, Nicholl BI, McQueenie R, Connelly DT, Hanlon P, Gallacher KI, Lee D, Mair FS. Multimorbidity and co-morbidity in atrial fibrillation and effects on survival: findings from UK Biobank cohort. Europace. 2018;20:f329–f336.

    Article  PubMed  Google Scholar 

  8. Hart RG, Pearce LA, Aguilar MI. Adjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation. Ann Intern Med 2007;147:590–592.

    Article  PubMed  Google Scholar 

  9. Mant J, Hobbs FD, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, Murray E, BAFTA investigators, Midland Research Practices Network (MidReC).Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation(the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007;370:493–503.

    Article  CAS  PubMed  Google Scholar 

  10. Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, Haeusler KG, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N, Sinnaeve P, Collins R, Camm AJ, Heidbüchel H; ESC Scientific Document Group. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018 Apr 21;39(16):1330–1393. doi: https://doi.org/10.1093/eurheartj/ehy136.

    Article  CAS  PubMed  Google Scholar 

  11. Camm AJ, Fox KAA, Peterson E. Challenges in comparing the non-vitamin K antagonist oral anticoagulants for atrial fibrillation-related stroke prevention. Europace. 2018 Jan 1;20(1):1–11. doi: https://doi.org/10.1093/europace/eux086.

    Article  PubMed  Google Scholar 

  12. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011 Sep 8;365(10):883–91. doi: https://doi.org/10.1056/NEJMoa1009638. Epub 2011 Aug 10.

    Article  CAS  PubMed  Google Scholar 

  13. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Špinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013 Nov 28;369(22):2093–104. doi: https://doi.org/10.1056/NEJMoa1310907. Epub 2013 Nov 19.

    Article  CAS  PubMed  Google Scholar 

  14. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011 Sep 15;365(11):981–92. doi: https://doi.org/10.1056/NEJMoa1107039. Epub 2011 Aug 27.

    Article  CAS  PubMed  Google Scholar 

  15. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009 Sep 17;361(12):1139–51. doi: https://doi.org/10.1056/NEJMoa0905561. Epub 2009 Aug 30.

    Article  CAS  PubMed  Google Scholar 

  16. Xarelto 20 mg Fachinformation. August 2018. Bayer AG.

  17. Lixiana 60 mg Fachinformation. August 2018. Daiichi Sankyo Europe GmbH.

  18. Pradaxa 150 mg Fachinformation. Juni 2018. Boehringer Ingelheim International GmbH

  19. Eliquis 5 mg Fachinformation. Februar 2019. Bristol-Myers Squibb/Pfizer.

  20. Hammersley D, Signy M. Navigating the choice of oral anticoagulation therapy for atrial fibrillation in the NOAC era. Ther Adv Chronic Dis. 2017 Dec;8(12):165–176. doi: https://doi.org/10.1177/2040622317720106. Epub 2017 Jul 26. Review.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Patti G, Lucerna M, Pecen L, Siller-Matula JM, Cavallari I, Kirchhof P, De Caterina R. Thromboembolic Risk, Bleeding Outcomes and Effect of Different Antithrombotic Strategies in Very Elderly Patients With Atrial Fibrillation: A Sub-Analysis From the PREFER in AF (Prevention oF Thromboembolic Events—European Registry in Atrial Fibrillation). J Am Heart Assoc. 2017;6:e005657.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Chao TF, Liu CJ, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Liao JN, Chung FP, Chen TJ, Lip GYH, Chen SA. Oral Anticoagulation in Very Elderly Patients With Atrial Fibrillation: A Nationwide Cohort Study.Circulation. 2018;138:37–47.

    Article  PubMed  Google Scholar 

  23. De Caterina R, Lip GYH. The non-vitamin K antagonist oral anticoagulants (NOACs) and extremes of body weight-a systematic literature review. Clin Res Cardiol. 2017 Aug;106(8):565–572. doi: https://doi.org/10.1007/s00392-017-1102-5. Epub 2017 Apr 10.

    Article  CAS  PubMed  Google Scholar 

  24. Boriani G, Ruff CT, Kuder JF, Shi M, Lanz HJ, Rutman H, Mercuri MF, Antman EM, Braunwald E, Giugliano RP. Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial. Eur Heart J. 2019 May 14;40(19):1541–1550. doi: https://doi.org/10.1093/eurheartj/ehy861.

    Article  PubMed  Google Scholar 

  25. Hohnloser SH, Fudim M, Alexander JH, Wojdyla DM, Ezekowitz JA, Hanna M, Atar D, Hijazi Z, Bahit MC, Al-Khatib SM, Lopez-Sendon JL, Wallentin L, Granger CB, Lopes RD. Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight. Circulation. 2019 May 14;139(20):2292–2300. doi: https://doi.org/10.1161/CIRCULATIONAHA.118.037955.

    Article  CAS  PubMed  Google Scholar 

  26. Di Minno MN, Ambrosino P, Dentali F. Safety of warfarin in „high-risk“ populations: A meta-analysis of randomized and controlled trials. Thromb Res. 2017 Feb;150:1–7. doi: https://doi.org/10.1016/j.thromres.2016.12.005. Epub 2016 Dec 9.

    Article  CAS  PubMed  Google Scholar 

  27. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW: Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 2003;42:1050–1065.

    Article  CAS  PubMed  Google Scholar 

  28. Olesen JB, Lip GY, Kamper AL, Hommel K, Køber L, Lane DA, Lindhardsen J, Gislason GH, Torp-Pedersen C. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med. 2012 Aug 16;367(7):625–35. doi: https://doi.org/10.1056/NEJMoa1105594.

    Article  CAS  PubMed  Google Scholar 

  29. Nochaiwong S, Ruengorn C, Awiphan R, Dandecha P, Noppakun K, Phrommintikul A. Efficacy and safety of warfarin in dialysis patients with atrial fibrillation: a systematic review and meta-analysis. Open Heart. 2016 Jun 16;3(1):e000441. doi: https://doi.org/10.1136/openhrt-2016-000441. eCollection 2016.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Qamar A, Vaduganathan M, Greenberger NJ, Giugliano RP. Oral Anticoagulation in Patients With Liver Disease. J Am Coll Cardiol. 2018 May 15;71(19):2162–2175. doi: https://doi.org/10.1016/j.jacc.2018.03.023.

    Article  CAS  PubMed  Google Scholar 

  31. Tripodi A, Primignani M, Mannucci PM, Caldwell SH. Changing Concepts of Cirrhotic Coagulopathy. Am J Gastroenterol. 2017 Feb;112(2):274–281. doi: https://doi.org/10.1038/ajg.2016.498. Epub 2016 Nov 1.

    Article  PubMed  Google Scholar 

  32. Goriacko P, Veltri KT. Safety of direct oral anticoagulants vs warfarin in patients with chronic liver disease and atrial fibrillation. Eur J Haematol. 2018 May;100(5):488–493. doi: https://doi.org/10.1111/ejh.13045. Epub 2018 Mar 13.

    Article  CAS  PubMed  Google Scholar 

  33. Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, Maeng M, Merkely B, Zeymer U, Gropper S, Nordaby M, Kleine E, Harper R, Manassie J, Januzzi JL, Ten Berg JM, Steg PG, Hohnloser SH; RE-DUAL PCI Steering Committee and Investigators. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. N Engl J Med. 2017 Oct 19;377(16):1513–1524. doi: https://doi.org/10.1056/NEJMoa1708454. Epub 2017 Aug 27.

    Article  CAS  PubMed  Google Scholar 

  34. Gibson CM, Mehran R, Bode C, Halperin J, Verheugt F, Wildgoose P, van Eickels M, Lip GY, Cohen M, Husted S, Peterson E, Fox K. An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). Am Heart J. 2015 Apr;169(4):472–8.e5. doi: https://doi.org/10.1016/j.ahj.2014.12.006. Epub 2014 Dec 20.

    Article  CAS  PubMed  Google Scholar 

  35. Lopes RD, Heizer G, Aronson R, Vora AN, Massaro T, Mehran R, Goodman SG, Windecker S, Darius H, Li J, Averkov O, Bahit MC, Berwanger O, Budaj A, Hijazi Z, Parkhomenko A, Sinnaeve P, Storey RF, Thiele H, Vinereanu D, Granger CB, Alexander JH; AUGUSTUS Investigators. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. N Engl J Med. 2019 Apr 18;380(16):1509–1524. doi: https://doi.org/10.1056/NEJMoa1817083. Epub 2019 Mar 17.

    Article  CAS  PubMed  Google Scholar 

  36. Vranckx P, Valgimigli M, Eckardt L, Tijssen J, Lewalter T, Gargiulo G, Batushkin V, Campo G, Lysak Z, Vakaliuk I, Milewski K, Laeis P, Reimitz PE, Smolnik R, Zierhut W, Goette A. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet. 2019 Oct 12;394(10206):1335–1343. doi: https://doi.org/10.1016/S0140-6736(19)31872-0. Epub 2019 Sep 3.

    Article  CAS  PubMed  Google Scholar 

  37. Flaker GC, Pogue J, Yusuf S, Pfeffer MA, Goldhaber SZ, Granger CB, Anand IS, Hart R, Connolly SJ; Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE) Investigators. Cognitive function and anticoagulation control in patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2010 May;3(3):277–83. doi: https://doi.org/10.1161/CIRCOUTCOMES.109.884171. Epub 2010 Mar 16.

    Article  PubMed  Google Scholar 

  38. Jacobs LG, Billett HH, Freeman K, Dinglas C, Jumaquio L. Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage dementia: a single-center, retrospective, observational study. Am J Geriatr Pharmacother 2009;7:159–166.

    Article  PubMed  Google Scholar 

  39. Banerjee A, Clementy N, Haguenoer K, Fauchier L, Lip GY. Prior history of falls and risk of outcomes in atrial fibrillation: the Loire Valley Atrial Fibrillation Project. Am J Med 2014;127:972–978.

    Article  PubMed  Google Scholar 

  40. Mosarla RC, Vaduganathan M, Qamar A, Moslehi J, Piazza G, Giugliano RP. Anticoagulation Strategies in Patients With Cancer: JACC Review Topic of the Week. J Am Coll Cardiol. 2019 Mar 26;73(11):1336–1349. doi: https://doi.org/10.1016/j.jacc.2019.01.017. Review.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014 Mar 15;383(9921):955–62. doi: https://doi.org/10.1016/S0140-6736(13)62343-0. Epub 2013 Dec 4.

    Article  CAS  PubMed  Google Scholar 

  42. Holmes DR Jr, Doshi SK, Kar S, Price MJ, Sanchez JM, Sievert H, Valderrabano M, Reddy VY. Left Atrial Appendage Closure as an Alternative to Warfarin for Stroke Prevention in Atrial Fibrillation: A Patient-Level Meta-Analysis. J Am Coll Cardiol 2015;65:2614–23.

    Article  PubMed  Google Scholar 

  43. Qureshi AI, Tuhrim S, Broderick JP, Batjer HH, Hondo H, Hanley DF. Spontaneous intracerebral hemorrhage. N Engl J Med. 2001 May 10;344(19):1450–60.

    Article  CAS  PubMed  Google Scholar 

  44. Turagam MK, Velagapudi P, Flaker GC. Stroke prevention in the elderly atrial fibrillation patient with comorbid conditions: focus on non-vitamin K antagonist oral anticoagulants. Clin Interv Aging. 2015;10:1431–44.

    CAS  PubMed  PubMed Central  Google Scholar 

  45. Meier B, Blaauw Y, Khattab AA, Lewalter T, Sievert H, Tondo C, Glikson M; Document Reviewers. EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion. Europace. 2014;16:1397–416.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Peter Osypka Herzzentrum München, Internistisches Klinikum München Süd, Am Isarkanal 36, D-81379, München, Deutschland

    Clemens Jilek &  Thorsten Lewalter

Authors
  1. Clemens Jilek
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thorsten Lewalter
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Clemens Jilek.

Additional information

Zusatzmaterial online:

Zu diesem Beitrag ist unter www.springermedizin.de/mmw Zusatzmaterial abrufbar: — Tab. 3: Kriterien zur Reduktion von NOAK-Substanzen, Kontraindikation und Warnhinweise/Interaktionen nach Fachinformationen

Electronic supplementary material

15006_2020_261_MOESM1_ESM.pdf

Tab. 3 Kriterien zur Reduktion von NOAK-Substanzen, Kontraindikation und Warnhinweise/Interaktionen nach Fachinformationen

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jilek, C., Lewalter, T. Antikoagulation unter erschwerten Bedingungen. MMW - Fortschritte der Medizin 162, 36–44 (2020). https://doi.org/10.1007/s15006-020-0261-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15006-020-0261-x

Keywords

Search

Navigation